BTNL2 Antibody | 22-717

BTNL2 Antibody | 22-717 | Gentaur UK, US & Europe Distribution

Host: Rabbit

Reactivity: Human, Mouse

Homology: N/A

Immunogen: Recombinant fusion protein containing a sequence corresponding to amino acids 246-455 of human BTNL2 (NP_062548.1) .

Research Area: Immunology

Tested Application: WB

Application: WB: 1:500 - 1:2000

Specificiy: N/A

Positive Control 1: HepG2

Positive Control 2: BT-474

Positive Control 3: HL-60

Positive Control 4: 293T

Positive Control 5: Mouse liver

Positive Control 6: N/A

Molecular Weight: Observed: 60kDa

Validation: N/A

Isoform: N/A

Purification: Affinity purification

Clonality: Polyclonal

Clone: N/A

Isotype: IgG

Conjugate: Unconjugated

Physical State: Liquid

Buffer: PBS with 0.02% sodium azide, 50% glycerol, pH7.3.

Concentration: N/A

Storage Condition: Store at -20˚C. Avoid freeze / thaw cycles.

Alternate Name: BTL-II, BTN7, HSBLMHC1, SS2, butyrophilin-like protein 2, butyrophilin-like 2 (MHC class II associated) , truncated BTNL2

User Note: Optimal dilutions for each application to be determined by the researcher.

BACKGROUND: This gene encodes a major histocompatibility complex, class II associated, type I transmembrane protein which belongs to the butyrophilin-like B7 family of immunoregulators. It is thought to be involved in immune surveillance, serving as a negative T-cell regulator by decreasing T-cell proliferation and cytokine release. The encoded protein contains an N-terminal signal peptide, two pairs of immunoglobulin-like domains, separated by a heptad peptide sequence, and a C-terminal transmembrane domain. Naturally occurring mutations in this gene are associated with sarcoidosis, rheumatoid arthritis, ulcerative colitis, inflammatory bowel disease, myositis, type 1 diabetes, systemic lupus erythematosus, acute coronary syndrome, and prostate cancer.